查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995538

嗜中性白血球低下症治療市場：2026-2032年全球市場預測（按治療方法、療法分類、給藥途徑、患者年齡層、嚴重程度、分銷管道和最終用戶分類）

Neutropenia Treatment Market by Treatment Type, Therapy Class, Route Of Administration, Patient Age Group, Severity, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，嗜中性白血球低下症治療市場價值將達到 158.5 億美元，到 2026 年將成長至 166.5 億美元，到 2032 年將達到 225.4 億美元，複合年成長率為 5.16%。

主要市場統計數據
基準年 2025 158.5億美元
預計年份：2026年 166.5億美元
預測年份：2032年 225.4億美元
複合年成長率 (%) 5.16%

簡要概述目前影響醫療保健專業人員和相關人員選擇中性粒細胞減少嗜中性白血球低下症治療方案的臨床、運作和商業性現實。

嗜中性白血球低下症仍然是腫瘤科、血液科以及許多住院和門診環境中的核心臨床挑戰，需要採用既能降低感染疾病風險又能確保及時繼續進行疾病修正治療的治療方法。過去十年，生長因子生物學和藥物遞送技術的進步重塑了臨床實踐，但在藥物獲取、製劑模式以及支持安全居家給藥的基礎設施方面仍然存在顯著差異。本執行摘要整合了現代臨床實踐、給藥機制和產業策略轉變，旨在為在複雜的治療和商業生態系統中尋求幫助的相關人員提供資訊。

生物相似藥、長效製劑、數位化監測和基於價值的採購等發展勢頭如何匯聚，從而重新定義嗜中性白血球低下症治療管道？

嗜中性白血球低下症的治療格局正在經歷一場變革性的轉變，監管、技術和商業性因素正在重塑治療方法的研發、交付和採購方式。其中一個顯著的變化是生物相似藥和可互換生技藥品的普及。這些藥物正在改變採購動態，並強化以支付主導的藥物管理模式。同時，由於長效製劑和最佳化給藥策略的出現，給藥頻率降低，這為更安全、更易於推廣的居家給藥方案鋪平了道路，也改變了醫院藥房和居家照護機構所需的服務模式。

評估美國計劃於 2025 年實施的關稅變化對嗜中性白血球低下症治療的供應鏈、採購行為和籌資策略的多方面影響。

近期貿易政策的發展以及宣布的2025年關稅調整，對用於治療嗜中性白血球低下症的生技藥品的治療供應鏈和籌資策略產生了多方面的影響。進口關稅的提高可能會增加成品和關鍵原料的進口成本，迫使生產商和經銷商重新評估其籌資策略和庫存緩衝。為此，企業可能會透過加快區域生產投資或實現供應商多元化，來保護利潤率並維持對醫院、門診中心和居家照護機構的持續供應，這些機構依賴穩定的Filgrastim、來諾格司亭和培Pegfilgrastim產品供應。

一個綜合性的細分框架，將治療方法、治療分類、給藥途徑、分銷管道和患者群體與可操作的策略重點聯繫起來。

從精細的市場區隔觀點，在嗜中性白血球低下症的治療中，臨床需求、商業策略和服務提供是如何相互交織的。治療類型分為非格Filgrastim）、PegfilgrastimFilgrastim細分為300微克、480微克和600微克三種劑量；來格司Pegfilgrastim進一步細分為3毫克和5毫克、480微克和600微克三種劑量；來格司庫這些差異會影響製劑模式、管瓶和注射器規格以及分銷合作夥伴的低溫運輸物流。在治療分類方面，生物相似藥和原廠藥被區分開來，這種區分會影響證據生成要求、價格談判和打入市場策略。

美洲、歐洲、中東和非洲以及亞太地區的市場動態和基礎設施差異決定了嗜中性白血球低下症治療的取得、採購和供應策略。

區域趨勢對嗜中性白血球低下症治療的可及性、監管預期和商業性實踐有顯著影響，每個宏觀區域都面臨著各自獨特的機會和挑戰。在美洲，相關人員必須應對影響生物相似藥和長效藥物普及的多元化支付體系，而先進的分銷網路和完善的居家照護基礎設施則為門診給藥的擴展提供了支持。監管差異在歐洲、中東和非洲尤為顯著。雖然成熟的歐洲市場擁有成熟的生物相似藥核准流程和集中採購流程，但中東和非洲部分地區在低溫運輸分銷和臨床醫生培訓方面面臨不同的基礎設施和限制。亞太地區的特點是產能快速擴張、生物相似藥研發生態系統蓬勃發展以及國內生產能力不斷增強，這既增強了當地供應的韌性，也帶來了價格競爭壓力。

決定中性粒細胞減少症治療中引入、簽約和供應韌性的原始製造商、生物相似藥參與企業和服務供應商之間的企業策略和競爭行為。

嗜中性白血球低下症治療領域的競爭動態由多家企業共同塑造，包括先鋒生物製藥企業、成熟的非專利和生物類似藥開發商，以及為低溫運輸和家庭輸液服務提供支持的專業契約製造和服務供應商。先鋒企業憑藉其臨床品牌價值和豐富的臨床試驗經驗，在與支付方談判和醫院製劑定位方面佔據優勢；而生物類似參與企業則利用其生產規模和成本效益高的管道贏得競標並擴大市場准入。一些企業也採取了類似的策略，透過以以金額為準的合約試點計畫來脫穎而出，這些計畫旨在簡化給藥方案、完善患者支持計畫並降低嗜中性白血球低下症減少症的住院率。

製造商、支付方和醫療保健提供者利用可操作的策略挑戰，在治療嗜中性白血球低下症方面協調證據、供應彈性和以患者為中心的服務模式。

行業領導者應優先進行一系列合作，協調臨床證據的獲取、供應鏈韌性以及與支付方的合作，以確保永續的藥物可及性和商業性可行性。首先，製藥公司應投資可操作的臨床試驗和真實世界數據（REW），以證明主導不僅具有臨床等效性，還能降低住院率和醫療資源利用率。此類證據是價值導向合約的基礎，並能增強公司在競標環境中的競爭力。其次，公司應實現製造地多元化，並與當地的灌裝和包裝合作夥伴共同製定緊急時應對計畫。這將有助於降低關稅波動和物流瓶頸帶來的營運風險，並確保醫院和居家照護機構的穩定供應。

一項嚴謹的混合方法研究途徑，結合了對臨床醫生的訪談、操作檢驗和二手文獻的整合，得出了實用的見解和現實的局限性。

本執行摘要所依據的研究整合了第一手和第二手研究，以確保提供可靠且多角度驗證的洞見，從而反映當前的臨床實踐和商業性趨勢。第一手研究包括對住院和門診臨床醫生、醫院系統供應鏈經理以及參與生技藥品採購和分銷的商業部門高管進行的結構化訪談。第二手研究包括同行評審的臨床文獻、監管指導文件以及對藥房和居家照護服務模式的營運分析。這些研究成果被整合起來，用於闡釋訪談結果並檢驗觀察到的趨勢。

綜合證據、供應彈性以及支付方合作將決定嗜中性白血球低下症治療的未來可及性和提供方式。

總而言之，嗜中性白血球低下症的治療格局正經歷著一場深刻的變革，其促進因素包括生物相似藥的引入、長效療法的普及、區域製造地的轉移以及支付方期望的轉變。這些因素共同影響著醫療服務的提供地點、產品的採購方式以及確保和維持治療方法在醫院、診所、居家照護和藥房等管道得到應用所需的證據。因此，臨床團隊和業務領導者必須採取綜合策略，涵蓋證據產生、供應鏈穩健性和差異化的市場進入，才能在日益以價值為導向的採購環境中取得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章嗜中性白血球低下症治療市場：依治療方法分類

  • Filgrastim
    • 300 mcg
    • 480 mcg
    • 600 mcg
  • 來諾格拉司亭
    • 3 mg
    • 5 mg

第9章嗜中性白血球低下症治療市場：依治療方法分類

  • 生物相似藥
  • 原廠產品

第10章嗜中性白血球低下症治療市場：依給藥途徑分類

  • 靜脈注射
  • 皮下注射

第11章嗜中性白血球低下症治療市場：依患者年齡層分類

  • 成人
  • 老年人
  • 兒童

第12章嗜中性白血球低下症治療市場：依嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第13章嗜中性白血球低下症治療市場：依通路分類

  • 醫院藥房
    • 住院藥房
    • 門診病人藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第14章嗜中性白血球低下症症治療市場：依最終用戶分類

  • 門診部
  • 診所
  • 居家照護
  • 醫院
    • 私人的
    • 民眾

第15章嗜中性白血球低下症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章嗜中性白血球低下症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章嗜中性白血球低下症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國嗜中性白血球低下症治療市場

第19章：中國嗜中性白血球低下症治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-FB6C9E793876

The Neutropenia Treatment Market was valued at USD 15.85 billion in 2025 and is projected to grow to USD 16.65 billion in 2026, with a CAGR of 5.16%, reaching USD 22.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.85 billion
Estimated Year [2026] USD 16.65 billion
Forecast Year [2032] USD 22.54 billion
CAGR (%) 5.16%

A concise orientation to the current clinical, operational, and commercial realities shaping neutropenia treatment choices across care settings and stakeholders

Neutropenia remains a central clinical challenge across oncology, hematology, and many inpatient and ambulatory care settings, demanding treatments that reduce infection risk while enabling the timely continuation of disease-modifying therapies. Advances in growth factor biology and drug delivery have reframed clinical practice over the past decade, yet significant variation persists in access, prescribing patterns, and the infrastructure that supports safe at-home administration. This executive summary synthesizes contemporary clinical practice, delivery mechanisms, and strategic industry shifts to inform stakeholders navigating a complex therapeutic and commercial ecosystem.

The context for decision-makers spans multiple care settings, from hospitals and clinics to home infusion services, where the interplay of safety protocols, reimbursement policies, and patient preferences shapes observable uptake. Clinicians increasingly weigh the comparative benefits of short-acting versus long-acting granulocyte-colony stimulating factors alongside considerations such as dosing convenience, adverse event profiles, and the operational burden on infusion units. Moreover, the dialogue around value-based procurement and biosimilar adoption has intensified, with procurement teams, payers, and providers recalibrating formularies to align clinical outcomes with cost and supply reliability. This introduction frames the subsequent sections by establishing the unmet needs, real-world operational constraints, and strategic levers that will define near-term decisions across commercial, clinical, and policy domains.

How biosimilar momentum, long-acting formulations, digital monitoring, and value-based purchasing are converging to redefine neutropenia treatment pathways

The neutropenia treatment landscape is undergoing transformative shifts driven by regulatory, technological, and commercial forces that are reshaping how therapies are developed, delivered, and procured. One prominent shift is the mainstreaming of biosimilars and interchangeable biologics, which have altered procurement dynamics and prompted intensified payer-led stewardship models. Concurrently, long-acting formulations and optimized dosing strategies have reduced administration frequency and opened the door to safer, more scalable home administration programs, changing the service mix required from hospital pharmacies and home care providers alike.

Emerging digital tools and remote monitoring platforms are enabling closer surveillance of neutropenic patients, allowing clinicians to identify infection risk earlier and triage care more effectively. This digital maturation is complemented by supply-chain innovations and regional manufacturing investments that seek to mitigate disruptions and support just-in-time delivery models. In parallel, value-based contracting and outcome-linked purchasing are gaining traction among larger integrated delivery networks, encouraging manufacturers to demonstrate not just clinical equivalence but measurable reductions in hospitalization and infection-related costs. These converging trends compel stakeholders to rethink product positioning, evidence generation strategies, and cross-functional collaboration to capture both clinical and economic value.

Assessing the multifaceted effects of the United States tariff changes slated for 2025 on supply chains, procurement behaviors, and sourcing strategies for neutropenia therapies

Recent trade policy developments and tariff adjustments announced for 2025 have a multifaceted impact on therapeutic supply chains and procurement strategies for biologic agents used in neutropenia management. Increased import tariffs can raise landed costs for finished products and critical raw materials, prompting manufacturers and distributors to reassess sourcing strategies and inventory buffers. In response, firms may accelerate regional manufacturing investments or alter supplier portfolios to protect margins and maintain supply continuity for hospitals, outpatient centers, and home care providers that depend on predictable deliveries of filgrastim, lenograstim, and pegfilgrastim products.

At the same time, purchasers and payers respond to higher acquisition costs by tightening formulary controls and reinforcing tender processes that emphasize total cost of care rather than unit price alone. This may amplify interest in biosimilar alternatives and stimulate contractual mechanisms that share risk between manufacturers and payers, such as outcomes-based agreements tied to reductions in febrile neutropenia-related admissions. Regulatory and compliance considerations also evolve under new tariff regimes, increasing the administrative burden on supply chain teams that must document provenance, harmonize customs classifications, and ensure continuity of cold chain logistics. Ultimately, the cumulative effect of tariff changes is to accelerate structural shifts toward localized production, diversified supply strategies, and closer payer-provider-manufacturer collaboration to preserve access and affordability in a constrained trade environment.

A comprehensive segmentation framework that links treatment modalities, therapy classes, administration routes, distribution channels, and patient cohorts to actionable strategic priorities

A nuanced segmentation lens reveals where clinical demand, commercial strategy, and service delivery intersect for neutropenia treatments. Treatment type divides into filgrastim, lenograstim, and pegfilgrastim, with filgrastim further differentiated into dosages of 300 mcg, 480 mcg, and 600 mcg, lenograstim split across 3 mg and 5 mg strengths, and pegfilgrastim typically represented by 6 mg dosing; these distinctions influence prescribing patterns, vial and syringe formats, and cold-chain logistics for distribution partners. The therapy class dimension separates biosimilar offerings from originator molecules, a distinction that drives evidence-generation requirements, pricing negotiations, and market access tactics.

Route of administration matters operationally and clinically, with intravenous injection and subcutaneous injection pathways shaping where care is delivered and how pharmacy services organize. Distribution channel segmentation includes hospital pharmacy, online pharmacy, and retail pharmacy, with hospital pharmacy further categorized into inpatient and outpatient pharmacy units, and retail pharmacy differentiated between chain and independent operators; these channels each present unique inventory management, reimbursement, and point-of-care education challenges. End user segmentation spans ambulatory care centers, clinics, home care, and hospitals, while hospitals themselves are segmented into private and public institutions, creating diverse institutional purchasing behaviors and formularies. Patient age group stratification into adult, geriatric, and pediatric cohorts highlights differential dosing, safety monitoring, and adherence support needs. Finally, severity-based segmentation classifies cases as mild, moderate, or severe neutropenia, which determines clinical urgency, prophylactic versus reactive use of colony-stimulating factors, and the intensity of supportive services required. This composite segmentation framework enables stakeholders to tailor clinical evidence, commercial tactics, and operational investments to the specific demands of each patient cohort and care setting.

Regional market dynamics and infrastructure variations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access, procurement, and delivery strategies for neutropenia therapies

Regional dynamics materially shape access, regulatory expectations, and commercial execution for neutropenia therapies, with each macro-region presenting distinct opportunities and constraints. In the Americas, stakeholders contend with heterogeneous payer systems that influence uptake of biosimilars and long-acting agents, while advanced distribution networks and strong home care infrastructure support expanded ambulatory administration. Europe, Middle East & Africa displays considerable regulatory diversity; established European markets often have mature biosimilar pathways and centralized procurement processes, whereas parts of the Middle East and Africa exhibit variable infrastructure and differing constraints on cold-chain distribution and clinician training. The Asia-Pacific region is marked by rapid capacity expansion, an active biosimilar development ecosystem, and growing domestic manufacturing that can improve local supply resilience but also introduces competitive pricing pressures.

Across these regions, differences in hospital ownership models, outpatient care penetration, and the maturity of home infusion services shape where product innovation and service models will gain traction. For multinational manufacturers and distributors, these regional contrasts require differentiated regulatory strategies, targeted evidence packages to meet local HTA expectations, and bespoke contracting approaches that reflect payer sophistication and procurement norms. Moreover, regional logistics and tariff environments interact with corporate sourcing decisions, so geographic diversification of manufacturing and warehousing is an essential consideration for sustaining consistent supply and meeting variable demand profiles across global markets.

Corporate strategies and competitive behaviors among originator manufacturers, biosimilar entrants, and service providers that determine adoption, contracting, and supply resilience in neutropenia care

Competitive dynamics in neutropenia treatment are shaped by a mix of originator biologic manufacturers, established generics and biosimilar developers, and specialized contract manufacturers and service providers that support cold chain and home infusion services. Originator companies retain clinical brand equity and deep clinical trial histories that support payer negotiations and hospital formulary positioning, while biosimilar entrants leverage manufacturing scale and cost-efficient pathways to win tenders and expand access. Parallel strategies are evident among companies investing to differentiate through reduced dosing regimens, patient support programs, and value-based contracting pilots that emphasize reduced hospitalization rates for febrile neutropenia.

Several manufacturers have prioritized integrated support services-ranging from nurse training for subcutaneous self-administration to digital adherence tools-to lower the operational burden on infusion centers and to make outpatient management more feasible. Contract manufacturing organizations and regional fill-and-finish partners have become critical for maintaining supply continuity, particularly in the context of tariff-induced resourcing shifts. Collectively, these company-level approaches underscore a competitive landscape where clinical evidence, service delivery, and supply resilience are as decisive as price in securing long-term adoption across hospitals, clinics, and home care providers.

Actionable strategic imperatives for manufacturers, payers, and providers to align evidence, supply resilience, and patient-centered service models for neutropenia therapies

Industry leaders should prioritize a coordinated set of actions that align clinical evidence generation, supply chain resilience, and payer engagement to secure sustainable access and commercial viability. First, manufacturers should invest in pragmatic trials and real-world evidence that demonstrate not only clinical equivalence but also reductions in hospitalizations and resource utilization; this evidence supports value-based contracting and strengthens positioning in tender-driven environments. Second, firms should diversify manufacturing footprints and develop contingency plans with regional fill-and-finish partners to mitigate the operational risk posed by tariff shifts and logistic bottlenecks, thereby protecting delivery reliability for hospitals and home care operators.

Third, stakeholders must deepen payer and provider partnerships that focus on total cost of care metrics and patient-centered outcomes; by aligning incentives, manufacturers can negotiate contracts that share risk and reward based on demonstrable reductions in febrile neutropenia complications. Fourth, expanding patient support services and training programs to enable safe subcutaneous or at-home administration will reduce system burden and improve patient experience, particularly for adult and geriatric cohorts. Fifth, commercial teams should tailor market access strategies by channel and end user, differentiating approaches for inpatient pharmacy, outpatient clinics, retail chains, and online pharmacies. Finally, embracing digital monitoring and telehealth integrations can strengthen adherence, enable early infection detection, and produce actionable data that reinforce the clinical and economic value of specific treatment regimens. Taken together, these actions create a defensible pathway to both clinical impact and commercial sustainability.

A rigorous mixed-methods research approach combining clinician interviews, operational validation, and secondary literature synthesis to produce actionable insights and practical limitations

The research underpinning this executive summary integrates both primary and secondary inputs to ensure robust, triangulated findings that reflect current clinical practice and commercial dynamics. Primary research included structured interviews with clinicians across inpatient and outpatient settings, supply chain leaders within hospital systems, and commercial executives involved in biologics procurement and distribution. Secondary research comprised peer-reviewed clinical literature, regulatory guidance documents, and operational analyses of pharmacy and home care delivery models, synthesized to contextualize interview insights and to validate observed trends.

Data were triangulated through iterative cross-validation exercises, where qualitative insights from interviews were compared against published clinical outcomes and policy reports to identify consistent themes and to flag areas requiring further primary inquiry. Quality assurance measures included expert review by clinical advisors and supply chain specialists to ensure that operational descriptions and strategic implications were accurate and actionable. Limitations are acknowledged: while the methodology prioritizes depth and practical relevance, certain jurisdictional specifics and confidential contracting terms are beyond the scope of the present analysis and would require targeted primary engagement for full elucidation. Nevertheless, the approach provides a rigorous foundation for decision-makers seeking to align clinical strategy with commercial execution.

Consolidated conclusions on how integrated evidence, supply resilience, and payer alignment will determine the future accessibility and delivery of neutropenia treatments

In summary, the neutropenia treatment environment is navigating a period of substantive change driven by biosimilar adoption, long-acting therapy availability, regional manufacturing shifts, and evolving payer expectations. These forces jointly influence where care is delivered, how products are procured, and what evidence is required to secure and sustain adoption across hospitals, clinics, home care, and pharmacy channels. Clinical teams and commercial leaders must therefore adopt integrated strategies that address evidence generation, supply-chain robustness, and differentiated market access to succeed in increasingly value-oriented procurement environments.

Moving forward, stakeholders who proactively align clinical outcomes with operational feasibility and payer priorities will be best positioned to deliver patient-centered care while preserving commercial viability. Continued monitoring of tariff and trade developments, coupled with investments in regional capacity and digital patient management, will be central to managing risk and realizing the full potential of therapeutic innovations. This conclusion underscores the imperative for collaborative, evidence-driven actions that translate into safer patient journeys and more sustainable service delivery models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neutropenia Treatment Market, by Treatment Type

  • 8.1. Filgrastim
    • 8.1.1. 300 mcg
    • 8.1.2. 480 mcg
    • 8.1.3. 600 mcg
  • 8.2. Lenograstim
    • 8.2.1. 3 mg
    • 8.2.2. 5 mg

9. Neutropenia Treatment Market, by Therapy Class

  • 9.1. Biosimilar
  • 9.2. Originator

10. Neutropenia Treatment Market, by Route Of Administration

  • 10.1. Intravenous Injection
  • 10.2. Subcutaneous Injection

11. Neutropenia Treatment Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Neutropenia Treatment Market, by Severity

  • 12.1. Mild
  • 12.2. Moderate
  • 12.3. Severe

13. Neutropenia Treatment Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
    • 13.1.1. Inpatient Pharmacy
    • 13.1.2. Outpatient Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy
    • 13.3.1. Chain Pharmacy
    • 13.3.2. Independent Pharmacy

14. Neutropenia Treatment Market, by End User

  • 14.1. Ambulatory Care Centers
  • 14.2. Clinics
  • 14.3. Home Care
  • 14.4. Hospitals
    • 14.4.1. Private
    • 14.4.2. Public

15. Neutropenia Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Neutropenia Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Neutropenia Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Neutropenia Treatment Market

19. China Neutropenia Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Amgen Inc.
  • 20.7. Baxter International Inc.
  • 20.8. Biocon Limited
  • 20.9. Celltrion, Inc.
  • 20.10. Coherus BioSciences, Inc.
  • 20.11. Fresenius Kabi AG
  • 20.12. Intas Pharmaceuticals Ltd.
  • 20.13. Pfizer Inc.
  • 20.14. Sandoz International GmbH
  • 20.15. Teva Pharmaceutical Industries Ltd.
  • 20.16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUTROPENIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUTROPENIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 265. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 266. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 270. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 273. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 278. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 279. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 282. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 286. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)